Literature DB >> 23533028

Molecular and clinical characterization of 25 individuals with exonic deletions of NRXN1 and comprehensive review of the literature.

Frédérique Béna1, Damien L Bruno, Mats Eriksson, Conny van Ravenswaaij-Arts, Zornitza Stark, Trijnie Dijkhuizen, Erica Gerkes, Stefania Gimelli, Devika Ganesamoorthy, Ann Charlotte Thuresson, Audrey Labalme, Marianne Till, Frédéric Bilan, Laurent Pasquier, Alain Kitzis, Christele Dubourgm, Massimiliano Rossi, Armand Bottani, Maryline Gagnebin, Damien Sanlaville, Brigitte Gilbert-Dussardier, Michel Guipponi, Arie van Haeringen, Marjolein Kriek, Claudia Ruivenkamp, Stylianos E Antonarakis, Britt Marie Anderlid, Howard R Slater, Jacqueline Schoumans.   

Abstract

This study aimed to elucidate the observed variable phenotypic expressivity associated with NRXN1 (Neurexin 1) haploinsufficiency by analyses of the largest cohort of patients with NRXN1 exonic deletions described to date and by comprehensively reviewing all comparable copy number variants in all disease cohorts that have been published in the peer reviewed literature (30 separate papers in all). Assessment of the clinical details in 25 previously undescribed individuals with NRXN1 exonic deletions demonstrated recurrent phenotypic features consisting of moderate to severe intellectual disability (91%), severe language delay (81%), autism spectrum disorder (65%), seizures (43%), and hypotonia (38%). These showed considerable overlap with previously reported NRXN1-deletion associated phenotypes in terms of both spectrum and frequency. However, we did not find evidence for an association between deletions involving the β-isoform of neurexin-1 and increased head size, as was recently published in four cases with a deletion involving the C-terminus of NRXN1. We identified additional rare copy number variants in 20% of cases. This study supports a pathogenic role for heterozygous exonic deletions of NRXN1 in neurodevelopmental disorders. The additional rare copy number variants identified may act as possible phenotypic modifiers as suggested in a recent digenic model of neurodevelopmental disorders.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23533028     DOI: 10.1002/ajmg.b.32148

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  46 in total

Review 1.  Excitatory/Inhibitory Balance and Circuit Homeostasis in Autism Spectrum Disorders.

Authors:  Sacha B Nelson; Vera Valakh
Journal:  Neuron       Date:  2015-08-19       Impact factor: 17.173

2.  Human Neuropsychiatric Disease Modeling using Conditional Deletion Reveals Synaptic Transmission Defects Caused by Heterozygous Mutations in NRXN1.

Authors:  ChangHui Pak; Tamas Danko; Yingsha Zhang; Jason Aoto; Garret Anderson; Stephan Maxeiner; Fei Yi; Marius Wernig; Thomas C Südhof
Journal:  Cell Stem Cell       Date:  2015-08-13       Impact factor: 24.633

3.  Systems Analysis of the 22q11.2 Microdeletion Syndrome Converges on a Mitochondrial Interactome Necessary for Synapse Function and Behavior.

Authors:  Avanti Gokhale; Cortnie Hartwig; Amanda A H Freeman; Julia L Bassell; Stephanie A Zlatic; Christie Sapp Savas; Trishna Vadlamudi; Farida Abudulai; Tyler T Pham; Amanda Crocker; Erica Werner; Zhexing Wen; Gabriela M Repetto; Joseph A Gogos; Steven M Claypool; Jennifer K Forsyth; Carrie E Bearden; Jill Glausier; David A Lewis; Nicholas T Seyfried; Jennifer Q Kwong; Victor Faundez
Journal:  J Neurosci       Date:  2019-03-04       Impact factor: 6.167

4.  Identification of candidate single-nucleotide polymorphisms in NRXN1 related to antipsychotic treatment response in patients with schizophrenia.

Authors:  Aaron Jenkins; José A Apud; Fengyu Zhang; Heather Decot; Daniel R Weinberger; Amanda J Law
Journal:  Neuropsychopharmacology       Date:  2014-03-14       Impact factor: 7.853

5.  A de novo microdeletion in NRXN1 in a Dutch patient with mild intellectual disability, microcephaly and gonadal dysgenesis.

Authors:  Zehra Agha; Zafar Iqbal; Tjitske Kleefstra; Christiane Zweier; Rolph Pfundt; Raheel Qamar; Hans VAN Bokhoven; Marjolein H Willemsen
Journal:  Genet Res (Camb)       Date:  2015-10-06       Impact factor: 1.588

Review 6.  Overview of mouse models of autism spectrum disorders.

Authors:  Alexandra L Bey; Yong-hui Jiang
Journal:  Curr Protoc Pharmacol       Date:  2014-09-02

7.  Calsyntenin-3 molecular architecture and interaction with neurexin 1α.

Authors:  Zhuoyang Lu; Yun Wang; Fang Chen; Huimin Tong; M V V V Sekhar Reddy; Lin Luo; Suchithra Seshadrinathan; Lei Zhang; Luis Marcelo F Holthauzen; Ann Marie Craig; Gang Ren; Gabby Rudenko
Journal:  J Biol Chem       Date:  2014-10-28       Impact factor: 5.157

8.  A Statistical Framework for Mapping Risk Genes from De Novo Mutations in Whole-Genome-Sequencing Studies.

Authors:  Yuwen Liu; Yanyu Liang; A Ercument Cicek; Zhongshan Li; Jinchen Li; Rebecca A Muhle; Martina Krenzer; Yue Mei; Yan Wang; Nicholas Knoblauch; Jean Morrison; Siming Zhao; Yi Jiang; Evan Geller; Iuliana Ionita-Laza; Jinyu Wu; Kun Xia; James P Noonan; Zhong Sheng Sun; Xin He
Journal:  Am J Hum Genet       Date:  2018-05-10       Impact factor: 11.025

Review 9.  New innovations: therapeutic opportunities for intellectual disabilities.

Authors:  Jonathan D Picker; Christopher A Walsh
Journal:  Ann Neurol       Date:  2013-09       Impact factor: 10.422

10.  A Cross-Disorder Method to Identify Novel Candidate Genes for Developmental Brain Disorders.

Authors:  Andrea J Gonzalez-Mantilla; Andres Moreno-De-Luca; David H Ledbetter; Christa Lese Martin
Journal:  JAMA Psychiatry       Date:  2016-03       Impact factor: 21.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.